Educational guides, regulatory frameworks, and practical insights on ISO 10993, EU MDR, and FDA biocompatibility compliance for medical device professionals.
Structured reference material covering the most important ISO 10993, EU MDR, and FDA frameworks for biological evaluation.
Comprehensive reference covering the primary ISO 10993-1 standard framework. Covers the biological evaluation process, contact categories, endpoint identification, test waiver strategy, and the 2025 lifecycle approach update.
Practical guide to writing ISO 10993 Biological Evaluation Plans and Reports. Covers document structure, required sections, scientific justification approach, and common errors that trigger notified body queries.
Strategic approach to biological evaluation planning — from device material identification through endpoint selection, existing data assessment, and risk-based documentation. Covers both EU MDR and FDA submission contexts.
Detailed reference covering the three key EU MDR annexes: Annex I General Safety and Performance Requirements (including §10 biocompatibility), Annex II Technical Documentation structure, and Annex III PMS requirements.
Complete reference for the 2020 FDA guidance on use of ISO 10993-1 for biocompatibility evaluation in 510(k), De Novo, and PMA submissions. Risk-based approach, endpoint assessment tables, and FDA reviewer expectations.
Structured reference for ISO 13485:2016 QMS requirements for medical device manufacturers. Covers document control, design controls, supplier management, production controls, CAPA, and audit requirements.
Comprehensive guide to ISO 14971:2019 risk management framework — hazard identification, risk estimation, risk control, residual risk evaluation, and benefit-risk analysis throughout the device lifecycle.
An overview of the international regulatory framework for medical devices — ISO 13485, ISO 14971, and ISO 10993 series. How these standards work together in EU MDR and FDA regulatory submissions.
Key biological endpoints required by ISO 10993-1 by contact category and duration.
This table provides a simplified reference based on ISO 10993-1:2025 guidance. Actual endpoint requirements depend on device contact type (surface, externally communicating, or implant), material composition, and clinical use. All endpoints should be evaluated in the context of a biological evaluation plan. Contact Arvind for a project-specific assessment.
QMS requirements for medical device manufacturers. Covers design controls, supplier management, production, CAPA, and complaint handling.
Risk management framework for identifying, evaluating, and controlling risks throughout the medical device lifecycle.
Primary biological evaluation standard — evaluation and testing within a risk management process. 2025 revision introduces lifecycle approach.
EU legal framework governing medical device safety, performance, and CE Mark approval. Superseded MDD 93/42/EEC.
FDA guidance on use of ISO 10993-1 for biocompatibility evaluation in 510(k), De Novo, and PMA device submissions.
EU guidance document for preparation of clinical evaluation reports under EU MDR requirements. Framework for systematic literature review and clinical data appraisal.
Beyond reference guides — detailed articles on ISO 10993, EU MDR, and FDA biocompatibility written by a practising consultant.
The 2025 revision fundamentally reframes how biological safety must be evaluated across the entire device lifecycle.
These two documents are consistently confused in submissions. Here is the definitive distinction and the most common mistake.
FDA additional information requests for biocompatibility are among the most common 510(k) delays. Avoid all five patterns.
These resources provide educational context. For a project-specific ISO 10993 assessment, book a free consultation with Arvind.